Merck KGaA - 10%+ Owner at Xilio Therapeutics, Inc.

Issuer-level insider activity

Identity Names, identifiers, and filing context for this profile. 1 identity field
Entity type
Company
Source evidence Original filing metadata and source links for verification. 1 source field
Source filing history
Open source filing history

No buys or sells have been reported by Merck KGaA since 06 Oct 2025

Reported holdings for Merck KGaA in Xilio Therapeutics, Inc.

Form 4 holding 10%+ Owner

Xilio Therapeutics, Inc.

Security class
Common Stock
Shares / value
680,825
Estimated value
$565,085
Report date
26 Oct 2021
Price
$0.8300
Ownership
Indirect
Form 4 holding 10%+ Owner

Xilio Therapeutics, Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
26 Oct 2021
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Xilio Therapeutics, Inc.

Security class
Series C Preferred Srock
Shares / value
0
Estimated value
Report date
26 Oct 2021
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount

Transaction history for Merck KGaA in Xilio Therapeutics, Inc.

Sym Class Transaction % SEC-reported value SEC-reported price Shares Shares after Date Ownership
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .